

F Xavier Lopez-Labrador

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6894941/publications.pdf>

Version: 2024-02-01

41
papers

1,915
citations

430874

18
h-index

315739

38
g-index

43
all docs

43
docs citations

43
times ranked

2386
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5692-5697.	7.1	401
2	Hepatitis C and liver transplantation. Journal of Hepatology, 2001, 35, 666-678.	3.7	277
3	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. Journal of Clinical Virology, 2018, 101, 11-17.	3.1	161
4	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 1997, 27, 959-965.	3.7	120
5	The Prognostic Relevance of the Nonstructural 5A Gene Interferon Sensitivity Determining Region Is Different in Infections with Genotype 1b and 3a Isolates of Hepatitis C Virus. Journal of Infectious Diseases, 1998, 177, 839-847.	4.0	113
6	Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. , 1999, 58, 215-220.		91
7	Recombination in Hepatitis C Virus. Viruses, 2011, 3, 2006-2024.	3.3	78
8	Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon. Hepatology, 1999, 29, 897-903.	7.3	73
9	Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates. Antiviral Therapy, 2008, 13, 481-494.	1.0	63
10	Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6. Antimicrobial Agents and Chemotherapy, 2016, 60, 2402-2416.	3.2	52
11	Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine, 2017, 35, 5799-5807.	3.8	51
12	Recommendations for the introduction of metagenomic high-throughput sequencing in clinical virology, part I: Wet lab procedure. Journal of Clinical Virology, 2021, 134, 104691.	3.1	42
13	Recommendations for the introduction of metagenomic next-generation sequencing in clinical virology, part II: bioinformatic analysis and reporting. Journal of Clinical Virology, 2021, 138, 104812.	3.1	39
14	Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2. Scientific Reports, 2021, 11, 24392.	3.3	36
15	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. Journal of Clinical Virology, 2018, 102, 77-83.	3.1	33
16	Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samples. Journal of Clinical Virology, 2021, 141, 104908.	3.1	28
17	Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antiviral Therapy, 2008, 13, 481-94.	1.0	26
18	Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Eurosurveillance, 2015, 20, .	7.0	24

#	ARTICLE	IF	CITATIONS
19	Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. <i>Liver Transplantation</i> , 2004, 10, 217-227.	2.4	19
20	Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. <i>World Journal of Virology</i> , 2013, 2, 6.	2.9	19
21	Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. <i>Vaccine</i> , 2017, 35, 7331-7338.	3.8	18
22	Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial. <i>Emerging Microbes and Infections</i> , 2022, 11, 1833-1842.	6.5	18
23	Comparative study of a modified competitive RT-PCR and amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. , 1999, 58, 35-43.		17
24	Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfecting patients. <i>Virus Research</i> , 2007, 130, 285-291.	2.2	15
25	A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts. <i>Journal of Medical Virology</i> , 2020, 92, 1065-1074.	5.0	11
26	A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area. <i>PLoS ONE</i> , 2020, 15, e0228351.	2.5	11
27	Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2004, 72, 575-585.	5.0	10
28	Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17. <i>Eurosurveillance</i> , 2018, 23, .	7.0	9
29	Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 328-339.	3.4	9
30	Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. <i>Journal of Clinical Virology</i> , 2016, 84, 32-38.	3.1	7
31	Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. <i>Eurosurveillance</i> , 2019, 24, .	7.0	7
32	Clinical relevance of genetic heterogeneity in HCV. <i>Future Virology</i> , 2010, 5, 33-49.	1.8	6
33	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. <i>Future Microbiology</i> , 2015, 10, 1759-1766.	2.0	5
34	Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1129.	2.6	4
35	Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	4
36	Retrospective screening for SARS-CoV-2 among influenza-like illness hospitalizations: 2018-2019 and 2019-2020 seasons, Valencia region, Spain. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 166-171.	3.4	4

#	ARTICLE	IF	CITATIONS
37	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. <i>Cellular Immunology</i> , 2022, 371, 104455.	3.0	4
38	Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. <i>Infection, Genetics and Evolution</i> , 2010, 10, 1252-1261.	2.3	3
39	Boceprevir in the treatment of chronic hepatitis C virus infection. <i>Virus Adaptation and Treatment</i> , 2011, , 7.	1.5	2
40	New developments in the management of hepatitis C virus infection: focus on boceprevir. <i>Biologics: Targets and Therapy</i> , 2012, 6, 249.	3.2	2
41	Hepatitis C virus genetic association to rate of liver fibrosis progression. , 2013, , .		2